Literature DB >> 12759142

Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat.

Attila Tóth1, Noémi Kedei, Yun Wang, Peter M Blumberg.   

Abstract

The vanilloid receptor VR1 is a nonspecific Ca(2+) channel, expressed in sensory neurons in the peripheral nervous system and in various brain regions, which is believed to be an important molecular integrator of several chemical (acid, vanilloids) and physical stimuli (heat) that cause pain. Recently, several endogenous ligands for VR1 have been identified such as arachidonyl ethanolamide (anandamide) and the more potent arachidonyl dopamine (AA-DO). Here, we further characterize AA-DO as a ligand for rat VR1, heterologously expressed in CHO and HEK293 cells. AA-DO inhibited the binding of [3H]RTX to VR1 with a K(d) value of 5.49 +/- 0.68 microM and with positive cooperativity (p = 1.89 +/- 0.27), indicating that AA-DO was about 5-fold more potent than anandamide in this system. The K(d) (9.7 +/- 3.3 microM), and p values (1.54 +/- 0.04) for the binding of AA-DO to spinal cord membranes are in good correlation with the CHO-VR1 data. AA-DO stimulated 45Ca(2+) uptake on CHO-VR1 and HEK-VR1 cells with EC(50) values of 4.76 +/- 1.43 and 7.17 +/- 1.64 microM and Hill coefficients of 1.28 +/- 0.11 and 1.13 +/- 0.13, respectively, consistent with the binding measurements. In contrast to anandamide, AA-DO induced virtually the same level of 45Ca(2+) uptake as did capsaicin (90 +/- 6.6% in the CHO cells expressing VR1 and 89.3 +/- 9.4% in HEK293 cells expressing VR1). In a time dependent fashion following activation, AA-DO partially desensitized VR1 both in 45Ca(2+) uptake assays (IC(50) = 3.24 +/- 0.84 microM, inhibition is 68.5 +/- 6.85%) as well as in Ca(2+) imaging experiments (35.8 +/- 5.1% inhibition) using the CHO-VR1 system. The extent of desensitization was similar to that caused by capsaicin itself. We conclude that AA-DO is a full agonist for VR1 with a potency in the low micromolar range and is able to significantly desensitize the cells in a time and dose dependent manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759142     DOI: 10.1016/s0024-3205(03)00310-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

Review 1.  The expanding field of cannabimimetic and related lipid mediators.

Authors:  Heather B Bradshaw; J Michael Walker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

2.  TRPV1 regulators mediate gentamicin penetration of cultured kidney cells.

Authors:  Sigrid E Myrdal; Peter S Steyger
Journal:  Hear Res       Date:  2005-06       Impact factor: 3.208

3.  Functional characterisation of the S512Y mutant vanilloid human TRPV1 receptor.

Authors:  Kathy G Sutton; Elizabeth M Garrett; A Richard Rutter; Timothy P Bonnert; Wolfgang Jarolimek; Guy R Seabrook
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

4.  Jejunal afferent nerve sensitivity in wild-type and TRPV1 knockout mice.

Authors:  Weifang Rong; Kirk Hillsley; John B Davis; Gareth Hicks; Wendy J Winchester; David Grundy
Journal:  J Physiol       Date:  2004-08-26       Impact factor: 5.182

5.  Multiple actions of anandamide on neonatal rat cultured sensory neurones.

Authors:  Rhian M Evans; Roderick H Scott; Ruth A Ross
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

Review 6.  Sensory and sympathetic nervous system control of white adipose tissue lipolysis.

Authors:  Timothy J Bartness; Y B Shrestha; C H Vaughan; G J Schwartz; C K Song
Journal:  Mol Cell Endocrinol       Date:  2009-09-10       Impact factor: 4.102

7.  TRPV1: A Potential Drug Target for Treating Various Diseases.

Authors:  Rafael Brito; Sandeep Sheth; Debashree Mukherjea; Leonard P Rybak; Vickram Ramkumar
Journal:  Cells       Date:  2014-05-23       Impact factor: 6.600

Review 8.  N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities.

Authors:  Urszula Grabiec; Faramarz Dehghani
Journal:  Cannabis Cannabinoid Res       Date:  2017-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.